Eloxx Pharmaceuticals (ELOX) vs OKYO Pharma (OKYO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
OKYO Pharma is the larger company by market cap ($72.9 million vs $61.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | OKYO |
|---|---|---|
| Share price | $15.18 | $1.39 |
| Market cap | $61.27M | $72.95M |
| 1-day change | +2.02% | -2.73% |
| YTD return | — | -32.85% |
| 1-year return | — | -37.95% |
| P/E ratio (TTM) | 4.31 | — |
| EPS (TTM) | $3.52 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $3.20 |
| 52-week low | $8.20 | $1.27 |
| Distance from 52-week high | -35.13% | -56.56% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +151.98% | +499.28% |
| Average volume | 46.44K | 94.59K |
| Shares outstanding | 4.04M | 52.48M |
| Employees | 10 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Healthcare · Biotechnology · 10 employees
About OKYO Pharma
OKYO stock →OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain.
Healthcare · Biotechnology · 5 employees
ELOX vs OKYO FAQ
Which is bigger, Eloxx Pharmaceuticals or OKYO Pharma?
OKYO Pharma (OKYO) is larger, with a market capitalization of $72.95M compared with $61.27M for Eloxx Pharmaceuticals (ELOX).
Are Eloxx Pharmaceuticals and OKYO Pharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.